Abbott Pays $670M to Settle Preterm Formula NEC Suits
Healthcare manufacturers face mounting scrutiny over specialized neonatal nutrition. Abbott announced a $670 million agreement to resolve widespread litigation concerning its specialty preterm infant formula products. The settlement addresses claims brought by approximately 2,000 plaintiffs who alleged that cow milk-based formulas contributed to necrotizing enterocolitis in premature infants.
Overview of the Preterm Infant Formula Litigation
The settlement partially resolves extensive legal disputes across state and federal courts in the United States. Specifically, the agreement resolves an Illinois case where a jury originally awarded $495 million in 2024. Accrued interest increased that individual judgment to nearly $600 million before the final settlement. Consequently, Abbott chose a collective resolution rather than continuing lengthy appellate challenges.
However, Abbott did not admit liability in the settlement agreement. The company maintained strong confidence in the safety and efficacy of its specialty products. Furthermore, corporate leadership noted that the agreement marks a critical step toward resolving thousands of pending claims.
Clinical Context and Pathophysiology of NEC
Necrotizing enterocolitis remains one of the most severe gastrointestinal emergencies in neonatal intensive care units. The disease predominantly affects low-birth-weight premature infants and carries a mortality rate exceeding 20 percent. Premature neonates exhibit immature intestinal mucosal barriers and altered microvascular regulation.
In addition, an underdeveloped gut microbiome significantly increases susceptibility to bacterial translocation and rapid tissue necrosis. Therefore, early enteral feeding choices represent a delicate balance between meeting caloric demands and protecting mucosal integrity for vulnerable patients often managed through specialized intensive care medicine protocols.
Evidence on Human Milk and Formula Safety
Current clinical guidelines strongly emphasize that mother's own milk or donor human milk provides optimal protection against bowel injury. Nevertheless, joint consensus statements from major regulatory and health agencies emphasize that evidence links elevated disease rates to the absence of human milk rather than direct formula toxicity.
Specialized preterm products provide essential macro- and micronutrients when human milk supplies are insufficient. Therefore, neonatologists rely on specialized formulas and fortifiers to prevent extrauterine growth restriction in vulnerable neonates, a topic extensively covered in professional paediatrics speciality courses.
Frequently Asked Questions
Q1: What did the Abbott settlement resolve?
The $670 million settlement partially resolved claims from roughly 2,000 plaintiffs regarding specialty cow milk-based preterm formulas and necrotizing enterocolitis.
Q2: Did Abbott admit liability in the settlement?
No, Abbott did not admit liability and affirmed that regulatory bodies continue to recognize the safety of preterm infant formulas.
Q3: Why is human milk preferred for premature infants?
Human milk provides essential bioactive factors and immunoglobulins that strengthen the mucosal barrier and significantly lower the risk of necrotizing enterocolitis.
References
- Abbott to pay $670 million to settle some preterm infant formula cases - ETHealthworld
- Quigley M, Embleton ND, Meader N, McGuire W. Donor human milk for preventing necrotising enterocolitis in very preterm or very low-birthweight infants. Cochrane Database of Systematic Reviews. 2024;9:CD002971.
- US Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health. Consensus Statement on Premature Infants and Necrotizing Enterocolitis. 2024.
